GlassScriptPhysician profile
Ashok N Melvani
NPI 1447334099
$9,991.22
in general payments reported to CMS, 2019-2025
36 companies · $1,416 in 2025
The $1,416 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $966 · 2020: $448 · 2021: $2,031 · 2022: $2,953 · 2023: $931 · 2024: $1,244 · 2025: $1,416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,592.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,591.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $2,049.15 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $1,269.22 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,236.51 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Empire Medical, INC | $1,200.00 | 2021 | |
| Abbott Laboratories | $823.01 | 2021-2025 | Freestyle Libre 3 |
| Pfizer INC. | $378.45 | 2019-2025 | |
| Lilly USA, LLC | $336.52 | 2021-2025 | Mounjaro, Taltz |
| Merck Sharp & Dohme LLC | $283.74 | 2019-2025 | Winrevair |
| Regeneron Healthcare Solutions, INC. | $250.00 | 2022-2023 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $245.12 | 2019-2025 | |
| Glaxosmithkline, LLC. | $221.80 | 2019-2024 | Trelegy Ellipta, Benlysta |
| Ucb, INC. | $188.51 | 2023-2025 | Bimzelx, Cimzia |
| Madrigal Pharmaceuticals | $150.00 | 2025 | Rezdiffra |
| Abbvie INC. | $128.00 | 2020-2024 | |
| Genzyme Corporation | $125.00 | 2025 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashok Melvani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.